Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,596 |
Ending reported balance
After 2026-08-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-25 · Exercise / conversion · Acquired 21,132 · Balance 52,728 Row 2 · 2026-08-25 · Exercise / conversion · Acquired 12,429 · Balance 65,157 Row 3 · 2026-08-25 · Sale · Disposed 33,561 · Balance 31,596 F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $194.12 · Expires 2033-05-26 | Direct | 7,044 |
Reported balance
After 2026-08-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-25 · Exercise / conversion · Disposed 21,132 · Balance 7,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $208.44 · Expires 2034-05-31 | Direct | 12,429 |
Reported balance
After 2026-08-25 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-25 · Exercise / conversion · Disposed 12,429 · Balance 12,429 |
| Common StockSEC Table I · non-derivative | Indirect2024 GRAT | 5,423 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,423 |
| Common StockSEC Table I · non-derivative | Indirect2025 GRAT | 10,780 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,780 |
| Common StockSEC Table I · non-derivative | Indirect2026 GRAT | 20,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 155,611 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 155,611 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust Held By Spouse | 10,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2019 Filed Feb 28, 2019 14:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $139.65 | $27,930.00 |
DisclosureSEC source: 0001127602-19-008802 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,089 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 70 | $139.65 | $9,775.15 |
DisclosureSEC source: 0001127602-19-008802 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,289 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:43 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,000 | $139.64 | $139,640.00 |
DisclosureSEC source: 0001127602-19-008802 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,359 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 25,123 | $0.00 Strike: $73.70 | $0.00 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · derivative · entry 24 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,124 Underlying: Common Stock · 25,123 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.64 | $13,963.50 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 23 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,359 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 130 | $139.63 | $18,151.90 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 22 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,459 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.63 | $13,962.50 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 21 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,589 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 30 | $139.62 | $4,188.60 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 20 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,689 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $139.61 | $27,922.00 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 19 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,719 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 210 | $139.60 | $29,316.00 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 18 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,919 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.60 | $13,959.50 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 17 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,129 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 605 | $139.59 | $84,451.95 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,229 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 99 | $139.58 | $13,818.42 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,834 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 177 | $139.57 | $24,703.89 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,933 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 171 | $139.56 | $23,864.76 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,110 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 30 | $139.55 | $4,186.50 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,281 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $139.54 | $27,908.00 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,311 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $139.52 | $41,856.00 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,511 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 345 | $139.51 | $48,130.95 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,811 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 38 | $139.49 | $5,300.62 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,156 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $139.46 | $55,784.00 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,194 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 147 | $139.45 | $20,499.15 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,594 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 53 | $139.44 | $7,390.32 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,741 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.43 | $13,943.00 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,794 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $139.34 | $69,670.00 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,894 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $139.33 | $13,933.00 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,394 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 14:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 25,123 | $73.70 | $1,851,565.10 |
DisclosureSEC source: 0001127602-19-008800 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $146.20 | $14,619.50 |
DisclosureSEC source: 0001127602-19-008344 · form4.xml · nonDerivative · entry 12 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,644 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $146.14 | $14,614.00 |
DisclosureSEC source: 0001127602-19-008344 · form4.xml · nonDerivative · entry 11 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,744 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $146.07 | $58,426.00 |
DisclosureSEC source: 0001127602-19-008344 · form4.xml · nonDerivative · entry 10 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,844 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $146.05 | $29,210.00 |
DisclosureSEC source: 0001127602-19-008344 · form4.xml · nonDerivative · entry 9 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,244 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $146.03 | $29,206.00 |
DisclosureSEC source: 0001127602-19-008344 · form4.xml · nonDerivative · entry 8 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,444 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 300 | $146.02 | $43,806.00 |
DisclosureSEC source: 0001127602-19-008344 · form4.xml · nonDerivative · entry 7 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,644 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $146.01 | $73,005.00 |
DisclosureSEC source: 0001127602-19-008344 · form4.xml · nonDerivative · entry 6 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,944 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $146.00 | $14,600.00 |
DisclosureSEC source: 0001127602-19-008344 · form4.xml · nonDerivative · entry 5 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,444 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $145.99 | $29,197.00 |
DisclosureSEC source: 0001127602-19-008344 · form4.xml · nonDerivative · entry 4 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,544 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $145.98 | $58,392.00 |
DisclosureSEC source: 0001127602-19-008344 · form4.xml · nonDerivative · entry 3 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,744 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 253 | $145.97 | $36,929.15 |
DisclosureSEC source: 0001127602-19-008344 · form4.xml · nonDerivative · entry 2 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,144 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:56 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 247 | $145.96 | $36,052.12 |
DisclosureSEC source: 0001127602-19-008344 · form4.xml · nonDerivative · entry 1 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,397 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $145.58 | $14,557.50 |
DisclosureSEC source: 0001127602-19-008340 · form4.xml · nonDerivative · entry 23 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,720 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $145.57 | $29,114.00 |
DisclosureSEC source: 0001127602-19-008340 · form4.xml · nonDerivative · entry 22 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,820 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 99 | $145.54 | $14,408.46 |
DisclosureSEC source: 0001127602-19-008340 · form4.xml · nonDerivative · entry 21 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,020 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $145.53 | $29,106.00 |
DisclosureSEC source: 0001127602-19-008340 · form4.xml · nonDerivative · entry 20 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,119 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 601 | $145.52 | $87,457.52 |
DisclosureSEC source: 0001127602-19-008340 · form4.xml · nonDerivative · entry 19 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,319 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $145.48 | $14,548.00 |
DisclosureSEC source: 0001127602-19-008340 · form4.xml · nonDerivative · entry 18 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,920 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $145.46 | $58,184.00 |
DisclosureSEC source: 0001127602-19-008340 · form4.xml · nonDerivative · entry 17 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,020 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 100 | $145.42 | $14,542.00 |
DisclosureSEC source: 0001127602-19-008340 · form4.xml · nonDerivative · entry 16 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,420 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 200 | $145.39 | $29,078.00 |
DisclosureSEC source: 0001127602-19-008340 · form4.xml · nonDerivative · entry 15 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,520 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $145.38 | $58,152.00 |
DisclosureSEC source: 0001127602-19-008340 · form4.xml · nonDerivative · entry 14 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,720 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 20:53 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 203 | $145.37 | $29,510.11 |
DisclosureSEC source: 0001127602-19-008340 · form4.xml · nonDerivative · entry 13 FOSTER JAMES C · CIK 0001141722 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,120 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.